This Viewpoint uses the case of adalimumab (Humira), the most profitable biologic drug sold in the United States, to discuss factors that limit product competition and the ability of the public to access less expensive but comparably effective biosimilars.
No takes yet. Share an insight, caveat, or question.
Gellad et al. (2019) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: